# Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

> **NCT00680186** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 2589 (actual)

## Conditions studied

- Thromboembolism

## Interventions

- **DRUG:** Warfarin
- **DRUG:** Dabigatran etexilate

## Key facts

- **NCT ID:** NCT00680186
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 2589 (ACTUAL)
- **Last updated:** 2014-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00680186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00680186, "Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00680186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*